These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25955657)

  • 1. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ; Hu YY; Lin XP; Fan W
    Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
    Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.
    Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y
    Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines.
    Yang C; Zhou Q; Li M; Tong X; Sun J; Qing Y; Sun L; Yang X; Hu X; Jiang J; Yan X; He L; Wan C
    Sci Rep; 2016 Sep; 6():33078. PubMed ID: 27609465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
    Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
    Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N
    Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R; Yin J; Zhang Y; Zhang S
    J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
    Ghanbarian M; Afgar A; Yadegarazari R; Najafi R; Teimoori-Toolabi L
    Biomed Pharmacother; 2018 Dec; 108():1070-1080. PubMed ID: 30372807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
    Chiu SJ; Lee YJ; Hsu TS; Chen WS
    Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance.
    Kalimutho M; Minutolo A; Grelli S; Formosa A; Sancesario G; Valentini A; Federici G; Bernardini S
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1299-312. PubMed ID: 20734047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
    Taniguchi K; Sugito N; Kumazaki M; Shinohara H; Yamada N; Nakagawa Y; Ito Y; Otsuki Y; Uno B; Uchiyama K; Akao Y
    Cancer Lett; 2015 Jul; 363(1):17-27. PubMed ID: 25818238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
    Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PKM2 Gene Silencing on the Proliferation and Apoptosis of Colorectal Cancer LS-147T and SW620 Cells.
    Ao R; Guan L; Wang Y; Wang JN
    Cell Physiol Biochem; 2017; 42(5):1769-1778. PubMed ID: 28746922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.